Rosiglitazone PPARγ Agonist for Myopia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myopia, such as atropine eye drops, are limited by side effects and unclear mechanisms, and there is a need for an alternative pharmaceutical candidate that can effectively slow myopia progression with lower toxicity and fewer adverse reactions.
Innovation Solution
A PPARγ agonist, specifically rosiglitazone or a pharmaceutically acceptable salt, is used to selectively bind to PPARγ without binding to PPARα, formulated into various administration forms to target refractive disorders like myopia or hyperopia, allowing delivery through the cornea and/or blood-retinal barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If atropine eye drops are used to treat myopia, then myopia progression is slowed, but side effects such as photophobia, blurry near vision, and allergic conjunctivitis increase
Solution Approach 1:
The patent extracts the beneficial effect of atropine (slowing myopia progression) while eliminating its harmful side effects by identifying and targeting the specific molecular pathway (M3 muscarinic receptor) responsible for the therapeutic effect, then developing selective antagonists that do not trigger the side effects
Solution Approach 2:
The invention applies local quality by designing drugs with selective affinity for specific receptor subtypes (M3 muscarinic receptor) in the eye, allowing the drug to act locally on the target tissue without affecting other systems that would cause systemic side effects
2Reliability
If higher doses of atropine are used to improve myopia control, then effectiveness increases, but toxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the drug molecule to create analogs with modified potency and selectivity profiles, allowing effective doses to be reduced while maintaining or improving therapeutic effect. This includes modifying the atropine molecular structure to create more selective M3 antagonists
3Ease of manufacture
If the mechanism of atropine action is not well understood, then clinical application is limited, but research progress is hindered
Solution Approach 1:
The patent employs feedback mechanisms by using proteomics and molecular biology techniques to monitor and understand the downstream effects of M3 receptor blockade, creating a feedback loop that connects clinical observations with molecular mechanism understanding, thereby advancing both basic science and clinical application
Data Source
AI summary
A pharmacologic treatment of refractive disorders, specifically myopia or hyperopia, by targeting the PPAR signaling pathway using a PPARγ agonist without any binding to PPARα. It is demonstrated that the PPARγ agonist modulates ocular growth through therapeutic intervention at the protein level of the PPAR signaling pathway. The effectiveness of the PPARγ agonist in regulating the PPAR signaling pathway and its associated proteins, as evidenced by experiments using a lens-induced myopia (LIM) animal model. More particularly, it is also demonstrated that the pharmacological reduction of myopic eye growth in terms of biometrics with dosage effect through the administration of the PPARγ agonist.